Teva Pharma Industries Stock Current Valuation
| TEVA Stock | USD 16.10 0.14 0.86% |
Valuation analysis of Teva Pharma Industries helps investors to measure Teva Pharma's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. The current year's Enterprise Value Over EBITDA is expected to grow to 67.62. The current year's Enterprise Value Multiple is expected to grow to 67.62. Fundamental drivers impacting Teva Pharma's valuation include:
Undervalued
Today
Please note that Teva Pharma's price fluctuation is not too volatile at this time. Calculation of the real value of Teva Pharma Industries is based on 3 months time horizon. Increasing Teva Pharma's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Teva Pharma is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Teva Stock. However, Teva Pharma's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 16.1 | Real 17.41 | Target 24.17 | Hype 16.1 | Naive 15.45 |
The real value of Teva Stock, also known as its intrinsic value, is the underlying worth of Teva Pharma Industries Company, which is reflected in its stock price. It is based on Teva Pharma's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Teva Pharma's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Teva Pharma Industries helps investors to forecast how Teva stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Teva Pharma more accurately as focusing exclusively on Teva Pharma's fundamentals will not take into account other important factors: Teva Pharma Industries Company Current Valuation Analysis
Teva Pharma's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Teva Pharma Current Valuation | 33.35 B |
Most of Teva Pharma's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Teva Pharma Industries is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Teva Current Valuation Driver Correlations
Understanding the fundamental principles of building solid financial models for Teva Pharma is extremely important. It helps to project a fair market value of Teva Stock properly, considering its historical fundamentals such as Current Valuation. Since Teva Pharma's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Teva Pharma's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Teva Pharma's interrelated accounts and indicators.
Click cells to compare fundamentals
Teva Current Valuation Historical Pattern
Today, most investors in Teva Pharma Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Teva Pharma's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current valuation growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Teva Pharma current valuation as a starting point in their analysis.
Teva Pharma Current Valuation |
| Timeline |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Teva Pharma Industries has a Current Valuation of 33.35 B. This is 132.16% higher than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The current valuation for all United States stocks is 100.58% lower than that of the firm.
Teva Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Teva Pharma's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Teva Pharma could also be used in its relative valuation, which is a method of valuing Teva Pharma by comparing valuation metrics of similar companies.Teva Pharma is currently under evaluation in current valuation category among its peers.
Teva Pharma Current Valuation Drivers
We derive many important indicators used in calculating different scores of Teva Pharma from analyzing Teva Pharma's financial statements. These drivers represent accounts that assess Teva Pharma's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Teva Pharma's important valuation drivers and their relationship over time.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Market Cap | 16.0B | 10.8B | 9.6B | 25.3B | 22.8B | 13.9B |
Teva Pharma ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Teva Pharma's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Teva Pharma's managers, analysts, and investors.Environmental | Governance | Social |
Teva Fundamentals
| Return On Equity | -0.28 | ||||
| Return On Asset | 0.0509 | ||||
| Profit Margin | (0.1) % | ||||
| Operating Margin | 0.21 % | ||||
| Current Valuation | 33.35 B | ||||
| Shares Outstanding | 1.15 B | ||||
| Shares Owned By Institutions | 60.32 % | ||||
| Number Of Shares Shorted | 27.81 M | ||||
| Price To Earning | 15.67 X | ||||
| Price To Book | 3.43 X | ||||
| Price To Sales | 1.13 X | ||||
| Revenue | 16.54 B | ||||
| Gross Profit | 8.06 B | ||||
| EBITDA | (303 M) | ||||
| Net Income | (1.96 B) | ||||
| Cash And Equivalents | 2.22 B | ||||
| Cash Per Share | 2.00 X | ||||
| Total Debt | 18.08 B | ||||
| Debt To Equity | 2.27 % | ||||
| Current Ratio | 0.99 X | ||||
| Book Value Per Share | 4.74 X | ||||
| Cash Flow From Operations | 1.25 B | ||||
| Short Ratio | 1.85 X | ||||
| Earnings Per Share | (1.45) X | ||||
| Price To Earnings To Growth | 0.97 X | ||||
| Target Price | 23.56 | ||||
| Number Of Employees | 33.89 K | ||||
| Beta | 0.83 | ||||
| Market Capitalization | 18.65 B | ||||
| Total Asset | 39.33 B | ||||
| Retained Earnings | (15.17 B) | ||||
| Working Capital | (244 M) | ||||
| Current Asset | 18.4 B | ||||
| Current Liabilities | 13.01 B | ||||
| Five Year Return | 2.95 % | ||||
| Net Asset | 39.33 B |
About Teva Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Teva Pharma Industries's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Teva Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Teva Pharma Industries based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Check out Teva Pharma Piotroski F Score and Teva Pharma Altman Z Score analysis. You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Teva Pharma. If investors know Teva will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Teva Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.4 | Earnings Share (1.45) | Revenue Per Share | Quarterly Revenue Growth (0.05) | Return On Assets |
The market value of Teva Pharma Industries is measured differently than its book value, which is the value of Teva that is recorded on the company's balance sheet. Investors also form their own opinion of Teva Pharma's value that differs from its market value or its book value, called intrinsic value, which is Teva Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Teva Pharma's market value can be influenced by many factors that don't directly affect Teva Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Teva Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Teva Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Teva Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.